CorMedix (CRMD) Stock Forecast & Price Target

$7.38

+0.14 (+1.93%)

(As of 12:12 PM ET)

CorMedix - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 5 Analyst Ratings

Based on 5 Wall Street analysts who have issued ratings for CorMedix in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for CRMD.

Consensus Price Target

$12.60
70.73% Upside

High Forecast	$19.00
Average Forecast	$12.60
Low Forecast	$9.00

According to the 5 analysts' twelve-month price targets for CorMedix, the average price target is $12.60. The highest price target for CRMD is $19.00, while the lowest price target for CRMD is $9.00. The average price target represents a forecasted upside of 70.73% from the current price of $7.38.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$12.60	$12.50	$13.00	$12.33
Forecasted Upside	70.73% Upside	160.82% Upside	225.81% Upside	184.83% Upside

China Stockpiling Gold “Like No Tomorrow” (Ad)

For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .

Click here now to get your free 'De-Dollarization' Guide.

CRMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CorMedix Stock vs. The Competition

Type	CorMedix	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	73.91% Upside	1,006.91% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/26/2024	Rodman & Renshaw 1 of 5 stars	Initiated Coverage	Buy	$13.00	+130.09%
8/15/2024	Royal Bank of Canada 4 of 5 stars	Reiterated Rating	Outperform ➝ Outperform	$9.00 ➝ $9.00	+87.89%
8/15/2024	Needham & Company LLC 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00	+103.25%
7/25/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$14.00 ➝ $12.00	+155.32%
4/9/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00	+299.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:49 PM ET.

CRMD Forecast - Frequently Asked Questions

What is CorMedix's forecast for 2024?: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for CorMedix is $12.60, with a high forecast of $19.00 and a low forecast of $9.00.
Should I buy or sell CorMedix stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRMD shares.
Does CorMedix's stock price have much upside?: According to analysts, CorMedix's stock has a predicted upside of 153.83% based on their 12-month stock forecasts.
What analysts cover CorMedix?: CorMedix has been rated by research analysts at Needham & Company LLC, Rodman & Renshaw, Royal Bank of Canada, and Truist Financial in the past 90 days.
Do Wall Street analysts like CorMedix more than its competitors?: Analysts like CorMedix more than other "medical" companies. The consensus rating for CorMedix is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRMD compares to other companies.